{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:11:23Z","timestamp":1774084283764,"version":"3.50.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001299","name":"Prevent Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001299","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.amjms.2022.04.019","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T11:04:47Z","timestamp":1650625487000},"page":"371-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care"],"prefix":"10.1016","volume":"364","author":[{"given":"Zachary L.","family":"Quinn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie A.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2022.04.019_bib0001","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.amjms.2022.04.019_bib0002","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"Aberle","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0003","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1200\/JCO.2006.07.2983","article-title":"Lung cancer incidence in never smokers","volume":"25","author":"Wakelee","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0004","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.amjms.2022.04.019_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9080107","article-title":"ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice","volume":"9","author":"Hofman","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.amjms.2022.04.019_bib0006","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.amjms.2022.04.019_bib0007","unstructured":"Network NCC: non-Small Cell Lung Cancer (Version 6.2021), 2021"},{"key":"10.1016\/j.amjms.2022.04.019_bib0008","unstructured":"National Comprehensive Cancer Network: non-small Cell Lung Cancer (Version 2.2021), 2020"},{"key":"10.1016\/j.amjms.2022.04.019_bib0009","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1513\/AnnalsATS.201801-045OC","article-title":"Adequacy of samples obtained by endobronchial ultrasound with transbronchial needle aspiration for molecular analysis in patients with non-small cell lung cancer. systematic review and meta-analysis","volume":"15","author":"Labarca","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.amjms.2022.04.019_bib0010","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/cncy.22085","article-title":"The role of cytology in molecular testing and personalized medicine in lung cancer: a clinical perspective","volume":"127","author":"Young","year":"2019","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0011","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1158\/1078-0432.CCR-07-1387","article-title":"Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method","volume":"13","author":"Pao","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjms.2022.04.019_bib0012","article-title":"Next generation sequencing technology in lung cancer diagnosis","volume":"10","author":"Cainap","year":"2021","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.amjms.2022.04.019_bib0013","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0014","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0015","doi-asserted-by":"crossref","first-page":"i38","DOI":"10.1093\/annonc\/mdx706","article-title":"Are liquid biopsies a surrogate for tissue EGFR testing?","volume":"29","author":"Goldman","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5301\/ijbm.5000256","article-title":"Tissue or blood: which is more suitable for detection of EGFR mutations in non-small cell lung cancer?","volume":"33","author":"Biaoxue","year":"2018","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.amjms.2022.04.019_bib0017","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjms.2022.04.019_bib0018","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1097\/CM9.0000000000001097","article-title":"Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response","volume":"133","author":"Li","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.amjms.2022.04.019_bib0019","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jtho.2020.05.002","article-title":"The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer","volume":"15","author":"Smeltzer","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0020","series-title":"Presented at the ASCO Annual Meeting, June 4, 2021","article-title":"Biomarker tissue mourney among patients with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practice","author":"EDN","year":"2021"},{"key":"10.1016\/j.amjms.2022.04.019_bib0021","series-title":"Presented at the ASCO Annual Meeting, June 4, 2021","article-title":"Biomarker tissue mourney among patients with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practice","author":"Robert","year":"2021"},{"key":"10.1016\/j.amjms.2022.04.019_bib0022","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/1055-9965.EPI-18-0917","article-title":"Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Non-Small Cell Lung Cancer Patients","volume":"28","author":"Palazzo","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.amjms.2022.04.019_bib0023","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12885-018-4190-3","article-title":"Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013","volume":"18","author":"Lynch","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.amjms.2022.04.019_bib0024","doi-asserted-by":"crossref","first-page":"26814","DOI":"10.18632\/oncotarget.4254","article-title":"A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives","volume":"6","author":"Russo","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.amjms.2022.04.019_bib0025","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.amjms.2022.04.019_bib0026","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0027","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","article-title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","volume":"372","author":"Kim","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjms.2022.04.019_bib0028","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0029","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0031","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0032","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000371821","article-title":"Acneiform Rash Induced by EGFR Inhibitors: review of the Literature and New Insights","volume":"1","author":"Fabbrocini","year":"2015","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.amjms.2022.04.019_bib0033","doi-asserted-by":"crossref","first-page":"e55128","DOI":"10.1371\/journal.pone.0055128","article-title":"Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.amjms.2022.04.019_bib0034","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0036","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0037","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: initial Results From the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0038","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2021.10.006","article-title":"A phase I\/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer","volume":"162","author":"Yasuda","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.amjms.2022.04.019_bib0039","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9580","article-title":"Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions","volume":"38","author":"Horn","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.amjms.2022.04.019_bib0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: a Phase 1\/2 Open-label Nonrandomized Clinical Trial","volume":"7","author":"Zhou","year":"2021","journal-title":"JAMA Oncol"},{"issue":"557","key":"10.1016\/j.amjms.2022.04.019_bib0041","article-title":"ALK Inhibitors in the Treatment of ALK Positive NSCLC","volume":"8","author":"Khan","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0042","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0043","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0044","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0045","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0046","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0047","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0048","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1158\/1078-0432.CCR-08-0646","article-title":"Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma","volume":"14","author":"Riely","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjms.2022.04.019_bib0049","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cancergen.2016.03.001","article-title":"The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma","volume":"209","author":"Biernacka","year":"2016","journal-title":"Cancer Genet"},{"key":"10.1016\/j.amjms.2022.04.019_bib0050","article-title":"The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)","volume":"2","author":"Salgia","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0051","series-title":"FDA Approval of KRAS Inhibitor Sotorasib For Lung Cancer Hailed as Milestone, Cancer Currents Blog","author":"Staff","year":"2021"},{"key":"10.1016\/j.amjms.2022.04.019_bib0052","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0054","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2010.33.1280","article-title":"Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations","volume":"29","author":"Paik","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0055","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0056","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0057","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0058","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0059","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMc1415359","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"372","author":"Shaw","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0061","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement","volume":"35","author":"Lim","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0062","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0063","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0064","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0065","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazieres","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0066","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1097\/JTO.0000000000000379","article-title":"NSCLC and HER2: between lights and shadows","volume":"9","author":"Ricciardi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0067","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.04.019_bib0068","first-page":"1","article-title":"Lung Cancer in Young Patients: higher Rate of Driver Mutations and Brain Involvement, but Better Survival","volume":"5","author":"Suidan","year":"2019","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.amjms.2022.04.019_bib0069","doi-asserted-by":"crossref","first-page":"e27486","DOI":"10.1002\/pbc.27486","article-title":"Understanding care and outcomes in adolescents and young adult with Cancer: a review of the AYA HOPE study","volume":"66","author":"Smith","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.amjms.2022.04.019_bib0070","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1038\/d41586-020-03150-2","article-title":"Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer","volume":"587","author":"Dolgin","year":"2020","journal-title":"Nature"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296292200180X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296292200180X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:16:03Z","timestamp":1762082163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000296292200180X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S000296292200180X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2022.04.019","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2022.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}